Analyst Reco. Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
5.2 ^USD	+0.58%		-7.64%	-48.67%

May. 30	Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	MT
May. 14	Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating	May. 30	MT
Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing	May. 14	MT
Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating	May. 09	MT
Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight	May. 09	MT
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating	Feb. 29	MT
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating	Jan. 03	MT
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating	Dec. 12	MT
Citigroup Upgrades Editas Medicine to Buy From Neutral, Price Target is $11	23-10-24	MT
ANALYST RECOMMENDATIONS : Dollar General, On Holding, Rio Tinto, Solaredge, Thermo Fisher...	23-10-24
JPMorgan Upgrades Editas Medicine to Neutral From Underweight, Price Target is $8	23-10-18	MT
Stifel Upgrades Editas Medicine to Buy From Hold, Adjusts Price Target to $17 From $9	23-09-29	MT
Chardan Cuts Price Target on Editas Medicine to $19 From $22, Maintains Buy Rating	23-08-03	MT
Raymond James Upgrades Editas Medicine to Outperform From Market Perform, Price Target is $17	23-06-13	MT
Credit Suisse Trims Editas Medicine's Price Target to $14 From $15, Keeps Neutral Rating	23-05-08	MT
RBC Lifts Price Target on Editas Medicine to $8 From $7, Maintains Sector Perform, Speculative Risk	23-05-08	MT
RBC Capital Adjusts Editas Medicine Price Target to $7 From $10, Maintains Sector Perform - Speculative Risk Rating	23-04-06	MT
Credit Suisse Raises Editas Medicine's Price Target to $15 From $13, Keeps Neutral Rating	23-02-23	MT
Chardan Adjusts Price Target on Editas Medicine to $22 From $35, Maintains Buy Rating	23-02-23	MT
Cantor Fitzgerald Starts Editas Medicine at Overweight With $15 Price Target	23-02-01	MT
Morgan Stanley Adjusts Editas Medicine's Price Target to $7 From $8, Keeps Underweight Rating	23-01-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Analyst Reco.

Filters